While diabetes or MASLD can drive a greater progression of liver fibrosis and risk of HCC, some therapies, such as metformin, GLP-1 Ras, or statins, might decrease the risk of HCC. This evidence concerns the gene GLP1R and hepatocellular carcinoma.